Novartis hustles along another FDA application for CAR-T star, tackling Gilead head on
Gilead likely won’t have DLBCL cancer to itself in the CAR-T arena for very long.
Novartis put out word early Tuesday that it has added positive 6-month data to its package on its CAR-T Kymriah (tisagenlecleucel) and sent it in to the FDA for their review on diffuse large B-cell lymphoma.
We don’t know what the 6-month data look like, but the pharma giant says it will tell all at the upcoming ASH conference in Atlanta in early December. Researchers have, however, spelled out a success after three months, just as Kite has.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
